Disclosure Context

Jupiter Life Line Hospitals Limited (Scrip Code: BSE: 543980, NSE: JLHL) submitted an investor presentation for the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026 (Q1 FY27) to the National Stock Exchange of India Ltd. and BSE Limited. The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document was signed and dated July 31, 2026, by Suma Upparatti, Company Secretary & Compliance Officer.

Management Commentary

Dr. Ankit Thakker, MD & CEO, provided commentary on the quarter. The Dombivli hospital completed its first full quarter of operations. Occupancy has been increasing steadily, supported by rising patient footfall, expansion of clinical services, and growing patient acceptance. The EBITDA loss from Dombivli was ₹9.5 crore for the quarter, which was stated to be in line with internal projections and earlier guidance. The process of insurance empanelment has been initiated, which is expected to further improve patient inflows in coming quarters. The company continues to add new specialties, strengthen its consultant base, and expand service offerings in line with its phased development strategy to support a steady ramp-up. Projects in Pune South, Mira Road, and BKC are continuing progress as previously discussed. The company's established hospitals were noted to maintain healthy occupancy levels, providing a stable financial and operational base.

Financial Performance Highlights (Consolidated)

Profit & Loss Statement (₹ in crore):

  • Income from Services: ₹1,499.8 crore for Q1 FY27.
  • Cost of Goods Sold: ₹287.3 crore.
  • Gross Profit: ₹1,212.5 crore, with a Gross Profit Margin of 80.8%.
  • Employee Cost: ₹256.3 crore.
  • Professional Fees: ₹364.0 crore.
  • Other Expenses: ₹248.9 crore.
  • EBITDA: ₹343.3 crore, with an EBITDA Margin of 22.9%.
  • Depreciation: ₹87.6 crore.
  • EBIT: ₹255.6 crore, with an EBIT Margin of 17.0%.
  • Other Income: ₹42.4 crore.
  • Finance Cost: ₹32.7 crore.
  • Exceptional Item Gain/(Loss): -₹4.9 crore.
  • PBT (Profit Before Tax): ₹260.4 crore, with a PBT Margin of 17.4%.
  • Tax: ₹66.2 crore.
  • PAT (Profit After Tax): ₹194.2 crore, with a PAT Margin of 12.9%.
  • Basic EPS: ₹29.59.

YoY Performance (Q1 FY27 vs Q1 FY26):

  • PAT decreased by 25.3% from ₹259.9 crore in Q1 FY26.
  • PBT decreased by 25.0% from ₹347.2 crore in Q1 FY26.
  • EBITDA decreased by 19.8% from ₹428.0 crore in Q1 FY26.

QoQ Performance (Q1 FY27 vs Q4 FY26):

  • PAT decreased by 14.7% from ₹227.7 crore in Q4 FY26.
  • PBT decreased by 18.1% from ₹318.3 crore in Q4 FY26.
  • EBITDA decreased by 7.5% from ₹371.3 crore in Q4 FY26.

Key factors impacting profitability included the initial ramp-up loss of ₹9.5 crore from the Dombivli hospital, higher marketing costs related to launch activities, higher depreciation following the commercialization of Dombivli, and higher finance costs due to increased debt for ongoing capital expenditure.

Operating Metrics

  • Operational Beds: 1,700 (includes census and non-census beds).
  • Average Occupancy Rate: 64%.
  • Out-patient Volume: 395,000.
  • In-patient Volume: 21,500.
  • ARPOB (Average Revenue Per Occupied Bed): ₹57,600 (rounded to nearest hundred).
  • ALOS (Average Length of Stay): 4.5 days.

Expansion and Capital Expenditure Plans

The company is in a significant expansion phase, scaling total bed capacity from 1,700 to 2,900 beds.

Recently Commissioned:

  • Dombivli: 500-bed capacity. Capex/Bed (Excl. Land): ₹1.0 crore. Phase-wise commissioning is underway, with approximately 200 beds operational and fit-outs completed for an additional 100 beds.

Greenfield Projects:

  • Pune II: 500-bed capacity. Capex/Bed (Excl. Land): ₹1.2 crore. Project is under construction.
  • Mira-Bhayandar: 300-bed capacity. Capex/Bed (Excl. Land): ₹1.3 crore. Project is currently at the conceptualization and planning stage.
  • BKC: 400-bed capacity. Capex/Bed (Excl. Land): ₹1.5 crore. Project is in the documentation and registration phase.

The post-IPO expansion involves adding 1,700 beds at an average cost per bed of approximately ₹1.5 crore. The strategic priorities for this expansion include utilizing a strategic land bank in high-demand micro markets, employing phased commissioning to optimize capital deployment, and achieving strong operating leverage from consolidated scale.